iBio and GE Healthcare (GE) form new global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines (IBIO) 1.29 : The alliance builds on the existing development and marketing agreement between the two companies announced in 2010 and combines iBio's plant-based vaccine manufacturing platform, iBioLaunch, with GE Healthcare's capabilities in start-to-finish technologies for biopharmaceutical manufacturing. iBio's research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology will continue to play a key role in advancing the iBioLaunch platform. Financial terms were not disclosed.
fast track to broad market use.. and royalty revenue imo
To follow my postings on ihub use this link : Ihub person mark
Feedback is allways appreciated, as are other (annotated) picks